Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Merck to acquire Verona Pharma for $10B, gaining Ohtuvayre, a breakthrough COPD treatment with rapid uptake since its 2024 launch.

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

General market weakness greeted the closing bell on Thursday on both sides of the border, as suspense reigned over whether a ...

Regions face reduced federal research funding and shrinking venture capital for startups, though rankings stay consistent.

Biogen said it intends to invest an additional $2 billion to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff.

Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.

Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.